Erratum to: Effect of Therapeutic Interventions on Health-related Quality of Life in Parkinson’s Disease

It is my pleasure to introduce the 2025 of touchREVIEWS in Neurology, which brings together an exceptional collection of reviews, original research and congress highlights that reflect the continued evolution of neurological science and clinical innovation. This issue opens with Jelle ...

Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of both upper and lower motor neurons, which ultimately leads to muscle weakness, atrophy, spasticity and contractures.1 ALS typically manifests in the 50–60 years age range, although familial cases may present in ...

The surge in social media use seems to have become a sign of our times. Social media has ramified into not only our personal lives but, importantly, also our professional lives and will continue to do so in the future.1–4 ...

Myoclonus is defined as a sudden, brief, lightning-like muscle contraction.1 It was first described by Friedreich in 1881 when he detailed sharp jerks involving the bulk of a full muscle without marked limb or joint movement and called it paramyoclonus multiplex.2 ...

It has been nearly 160 years since Friedreich’s ataxia (FRDA) was clinically recognized and described1 and 25 years since the FXN gene was discovered.2 Despite this, there are still no approved therapies for FRDA. FRDA is an autosomal, recessively inherited, neurodegenerative ...

Welcome to the spring edition of US Neurology. This journal aims to address topical subjects in the field of neurology to stimulate discussion focused on these issues. Articles have been chosen for their evaluation of current practices and research and ...

...

Welcome to the latest edition of European Neurological Review, which features a diverse range of topical articles covering a variety of therapeutic areas. This edition begins with a timely editorial from Milonas on recent advances in multiple sclerosis (MS), which ...

The clostridial neurotoxins (CNTs) (tetanus toxin [TeNT] and seven serologically distinct botulinum neurotoxins [BoNT/A–BoNT/D]), are among the deadliest agents known. They are bacterial enzymes produced by anaerobic, spore-forming bacteria of the genus Clostridium. Each toxin is composed ...

Patients with spastic paresis often endure prolonged treatment regimens, where each journey is patient-specific and often difficult. Spasticity – defined as increased, involuntary, velocity-dependent muscle tone that causes resistance to movement – is a complex condition that often causes pain, contractures and ...

Multiple system atrophy (MSA) is a is an adult-onset, sporadic, progressive neurodegenerative disease characterized by a varying combination of parkinsonism, cerebellar ataxia, autonomic failure, and corticospinal dysfunction. Patients either have a predominance of parkinsonian symptoms (MSA-P) such that they are ...

Parkinson’s disease (PD) has been traditionally defined by the motor symptoms of bradykinesia, resting tremor, rigidity and postural instability;1 however, more recently, it has been recognized that neuropsychiatric symptoms such as psychosis, anxiety, depression, apathy, impulse control disorders and ...